Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | GRM6 | O15303 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10102254 | 0.95 | ATM (0.39) | SMN1; SMN2TDP1ATML3MBTL1MAPT | |
| SCHEMBL7608091 | 0.93 | SMN1; SMN2 (0.41) | SMN1; SMN2NR4A2L3MBTL1MAPTKMT2A | |
| SCHEMBL13464551 | 0.92 | SMN1; SMN2 (0.38) | SMN1; SMN2TDP1NR4A2ATML3MBTL1 | |
| SCHEMBL8978512 | 0.91 | ATM (0.41) | SMN1; SMN2TDP1NR4A2ATML3MBTL1 | |
| SCHEMBL29913570 | 0.90 | KDM4E (0.36) | SMN1; SMN2TDP1NR4A2ATML3MBTL1 | |
| SCHEMBL8978570 | 0.90 | KDM4E (0.36) | SMN1; SMN2TDP1NR4A2ATML3MBTL1 | |
| SCHEMBL10102253 | 0.88 | SMN1; SMN2 (0.45) | SMN1; SMN2TDP1ATML3MBTL1MAPT | |
| SCHEMBL5645426 | 0.88 | SMN1; SMN2 (0.35) | SMN1; SMN2TDP1NR4A2ATML3MBTL1 | |
| SCHEMBL5159521 | 0.87 | SMN1; SMN2 (0.35) | SMN1; SMN2TDP1NR4A2ATML3MBTL1 | |
| SCHEMBL8978679 | 0.87 | SMN1; SMN2 (0.34) | SMN1; SMN2TDP1NR4A2ATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8308995-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20120138876-A1 | CHROMENE COMPOUND | KASAI SOKO (JP) | 2012-06-07 | — | — | US | disclosed |
| US-8147726-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20110062396-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120138876-A1 | CHROMENE COMPOUND | CHRM1, CBX8, CBX7 | SMN1; SMN2 1096/4885TDP1 1995/4885NR4A2 58/4885 |
| US-20110062396-A1 | CHROMENE COMPOUND | CDYL, NR0B1, NR1H2 | SMN1; SMN2 2922/4885TDP1 3349/4885NR4A2 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.